Epidemiology and antibiotic resistance of prosthetic joint infections according to time of occurrence, a 10-year study.
Anti-Bacterial Agents
/ pharmacology
Arthritis, Infectious
/ drug therapy
Cefotaxime
Coagulase
Drug Resistance, Microbial
Gram-Negative Bacteria
Humans
Imipenem
Microbial Sensitivity Tests
Piperacillin
Prosthesis-Related Infections
/ drug therapy
Retrospective Studies
Staphylococcus aureus
Tazobactam
Vancomycin
Bacterial distribution
Empirical antimicrobial therapy
Epidemiology
Prosthetic joint infection
Resistance
Time of occurrence
Journal
The Journal of infection
ISSN: 1532-2742
Titre abrégé: J Infect
Pays: England
ID NLM: 7908424
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
23
11
2021
revised:
03
07
2022
accepted:
08
07
2022
pubmed:
7
8
2022
medline:
19
10
2022
entrez:
6
8
2022
Statut:
ppublish
Résumé
To describe the microorganisms responsible for prosthetic joint infections (PJIs) and their antimicrobial susceptibilities, and to propose appropriate empirical antimicrobial treatments (EATs) according to time of occurrence METHODS: This 10-year retrospective study presents the bacterial etiology of 282 consecutive PJIs in a French hospital according to time of occurrence (adapted from Zimmerli's classification: early, <3 months; delayed, 3-12 months; late acute, >12 months with hematogenous seeding or contiguous spread; late chronic, >12 months without hematogenous seeding). The expected efficacy of various EATs was analyzed for each PJI. Staphylococci were the most commonly found bacteria (S. aureus (44.3%), coagulase-negative staphylococci (25.2%) with 15.2% and 49.3% methicillin resistance, respectively), followed by Gram-negative bacilli (GNB) (17.7%) and streptococci (14.9%). The distribution of species varied between categories, but antibiotics targeting GNBs were required in all categories. Imipenem-vancomycin was the most effective combination (99.3%) but should be reserved for patients with suspected resistant GNB. Cefotaxime-vancomycin was less effective in early/delayed and late PJIs (91.1% and 86.1%, respectively), due to resistant GNB and polymicrobial infections. Piperacillin/tazobactam-vancomycin appeared to be appropriate in all situations (>96% efficacy). Proposing universal recommendations remains challenging, but a good understanding of the local epidemiology is important for optimizing EATs.
Identifiants
pubmed: 35933039
pii: S0163-4453(22)00417-0
doi: 10.1016/j.jinf.2022.07.009
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Coagulase
0
Vancomycin
6Q205EH1VU
Imipenem
71OTZ9ZE0A
Cefotaxime
N2GI8B1GK7
Tazobactam
SE10G96M8W
Piperacillin
X00B0D5O0E
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
492-498Informations de copyright
Copyright © 2022 The British Infection Association. Published by Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.